Effect of Lanthanum Carbonate on Blood Pressure in CKD

Mitra S. Jamshidian; Brett Larive; Jennifer Gassman; Kalani L. Raphael; Michel B. Chonchol; Joachim H. Ix; Charles Ginsberg

doi:10.1053/j.ajkd.2020.12.012

Effect of Lanthanum Carbonate on Blood Pressure in CKD

Mitra S. Jamshidian, Brett Larive, Jennifer Gassman, Kalani L. Raphael, Michel B. Chonchol, Joachim H. Ix, Charles Ginsberg

Department of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	312-314
Number of pages	3
Journal	American Journal of Kidney Diseases
Volume	78
Issue number	2
DOIs	https://doi.org/10.1053/j.ajkd.2020.12.012
State	Published - Aug 2021

ASJC Scopus subject areas

Nephrology

Access to Document

10.1053/j.ajkd.2020.12.012

Cite this

@article{b49e1c0e2ac94e5caab34fcee755541e,

title = "Effect of Lanthanum Carbonate on Blood Pressure in CKD",

author = "Jamshidian, {Mitra S.} and Brett Larive and Jennifer Gassman and Raphael, {Kalani L.} and Chonchol, {Michel B.} and Ix, {Joachim H.} and Charles Ginsberg",

note = "Funding Information: For COMBINE (NCT02258074), Shire Pharmaceuticals donated LC and placebo, and Endurance Products Company donated nicotinamide and placebo. The trial was sponsored by the NIDDK Pilot Clinical Trials consortium (contracts U01DK097093 , U01DK099877 , U01DK099924 , U01DK099930 , and U01DK099933 ) with additional support from an ancillary study grant (R01DK102438). This study was also supported by grants from the NIDDK ( K23DK118197 ) and the Loan Repayment Program (CG), and grants R01DK101720 and K24 DK110427 (JHI). JHI was additionally supported by an Established Investigator Award from the American Heart Association ( 14EIA18560026 ). These funders played no role in the study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. Funding Information: Research idea and study design: CG, JHI, MSJ, JG; data acquisition: CG, JHI, KR; data analysis/interpretation: CG, JHI, MSJ, KR, MC; statistical analysis: BL, JG; supervision or mentorship: CG. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate. For COMBINE (NCT02258074), Shire Pharmaceuticals donated LC and placebo, and Endurance Products Company donated nicotinamide and placebo. The trial was sponsored by the NIDDK Pilot Clinical Trials consortium (contracts U01DK097093, U01DK099877, U01DK099924, U01DK099930, and U01DK099933) with additional support from an ancillary study grant (R01DK102438). This study was also supported by grants from the NIDDK (K23DK118197) and the Loan Repayment Program (CG), and grants R01DK101720 and K24 DK110427 (JHI). JHI was additionally supported by an Established Investigator Award from the American Heart Association (14EIA18560026). These funders played no role in the study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. The authors declare that they have no relevant financial interests. Received August 07, 2020. Evaluated by 2 external peer reviewers, with direct editorial input from a Statistics/Methods Editor and an Associate Editor, who served as Acting Editor-in-Chief. Accepted in revised form December 5, 2020. The involvement of an Acting Editor-in-Chief was to comply with AJKD's procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.",

year = "2021",

month = aug,

doi = "10.1053/j.ajkd.2020.12.012",

language = "English (US)",

volume = "78",

pages = "312--314",

journal = "American Journal of Kidney Diseases",

issn = "0272-6386",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Effect of Lanthanum Carbonate on Blood Pressure in CKD

AU - Jamshidian, Mitra S.

AU - Larive, Brett

AU - Gassman, Jennifer

AU - Raphael, Kalani L.

AU - Chonchol, Michel B.

AU - Ix, Joachim H.

AU - Ginsberg, Charles

N1 - Funding Information: For COMBINE (NCT02258074), Shire Pharmaceuticals donated LC and placebo, and Endurance Products Company donated nicotinamide and placebo. The trial was sponsored by the NIDDK Pilot Clinical Trials consortium (contracts U01DK097093 , U01DK099877 , U01DK099924 , U01DK099930 , and U01DK099933 ) with additional support from an ancillary study grant (R01DK102438). This study was also supported by grants from the NIDDK ( K23DK118197 ) and the Loan Repayment Program (CG), and grants R01DK101720 and K24 DK110427 (JHI). JHI was additionally supported by an Established Investigator Award from the American Heart Association ( 14EIA18560026 ). These funders played no role in the study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. Funding Information: Research idea and study design: CG, JHI, MSJ, JG; data acquisition: CG, JHI, KR; data analysis/interpretation: CG, JHI, MSJ, KR, MC; statistical analysis: BL, JG; supervision or mentorship: CG. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate. For COMBINE (NCT02258074), Shire Pharmaceuticals donated LC and placebo, and Endurance Products Company donated nicotinamide and placebo. The trial was sponsored by the NIDDK Pilot Clinical Trials consortium (contracts U01DK097093, U01DK099877, U01DK099924, U01DK099930, and U01DK099933) with additional support from an ancillary study grant (R01DK102438). This study was also supported by grants from the NIDDK (K23DK118197) and the Loan Repayment Program (CG), and grants R01DK101720 and K24 DK110427 (JHI). JHI was additionally supported by an Established Investigator Award from the American Heart Association (14EIA18560026). These funders played no role in the study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. The authors declare that they have no relevant financial interests. Received August 07, 2020. Evaluated by 2 external peer reviewers, with direct editorial input from a Statistics/Methods Editor and an Associate Editor, who served as Acting Editor-in-Chief. Accepted in revised form December 5, 2020. The involvement of an Acting Editor-in-Chief was to comply with AJKD's procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85104940378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104940378&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2020.12.012

DO - 10.1053/j.ajkd.2020.12.012

M3 - Letter

C2 - 33428997

AN - SCOPUS:85104940378

SN - 0272-6386

VL - 78

SP - 312

EP - 314

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

IS - 2

ER -

Effect of Lanthanum Carbonate on Blood Pressure in CKD

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this